1-7 of 7
Jinender Kumar
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Lisocabtagene Maraleucel (liso-cel) in Patients (pts) with Relapsed or Refractory (R/R) Follicular Lymphoma (FL): Transcend FL 2-Year Follow-up

Loretta Nastoupil, Saurabh Dahiya, Maria Lia Palomba, Alejandro Martín García-Sancho, Juan Luis Reguera, John Kuruvilla, Ulrich Jaeger, Guillaume Cartron, Koji Izutsu, Martin Dreyling, Brad S. Kahl, Herve Ghesquieres, Kirit Ardeshna, Hideki Goto, Anna Maria Barbui, Jeremy S. Abramson, Peter Borchmann, Isabelle Fleury, Stephan Mielke, Alan P Skarbnik, Manali Kamdar, Reem Karmali, Andreas Viardot, Thalia Farazi, Grace Shih Hui Kao, Min Vedal, Rina Nishii, Jessica Papuga, Jinender Kumar, Franck Morschhauser
Journal: Blood
Blood (2024) 144 (Supplement 1): 4387.
https://doi.org/10.1182/blood-2024-198509
Published: 2024
Journal Articles

Matching-Adjusted Indirect Comparison (MAIC) of Efficacy and Safety Outcomes for Lisocabtagene Maraleucel (liso-cel) Versus Axicabtagene Ciloleucel (axi-cel) and Tisagenlecleucel (tisa-cel) for the Treatment of Third-Line or Later (3L+) Relapsed or Refractory (R/R) Follicular Lymphoma (FL)

Alexander P. Boardman, Juan Luis Reguera, Paul Spin, Pearl Wang, Lamees Almuallem, Jenna Ellis, Jamie Zheng, Jinender Kumar, Thalia Farazi, Alejandro Martín García-Sancho, Koji Izutsu
Journal: Blood
Blood (2024) 144 (Supplement 1): 3028.
https://doi.org/10.1182/blood-2024-197948
Published: 2024
Journal Articles

Cost Consequence and Time Toxicity Model for the Treatment of Third-Line or Later (3L+) Follicular Lymphoma (FL) Using Advanced Therapies: A Comparison of Lisocabtagene Maraleucel (liso-cel) with Mosunetuzumab

Saurabh Dahiya, Ashley C. Saunders, Jinender Kumar, William Ngantung, Matia Saeedian
Journal: Blood
Blood (2024) 144 (Supplement 1): 3651.
https://doi.org/10.1182/blood-2024-201611
Published: 2024
Journal Articles

Patient-Reported Outcomes (PROs) from the Phase 2 TRANSCEND FL Study of Lisocabtagene Maraleucel (liso-cel) in Patients (pts) with Relapsed or Refractory Follicular Lymphoma (FL)

Guillaume Cartron, Alejandro Martin Garcia-Sancho, Juan Luis Reguera, Saurabh Dahiya, Shien Guo, Ling Shi, Laurie Eliason, Jinender Kumar, Thalia Farazi, Omotayo Fasan, Koji Izutsu
Journal: Blood
Blood (2023) 142 (Supplement 1): 668.
https://doi.org/10.1182/blood-2023-180175
Published: 2023
Journal Articles

Patient-Reported Outcomes from the MCL Cohort of the Phase 1, Seamless Design TRANSCEND NHL 001 Study of Lisocabtagene Maraleucel in Patients with R/R B-Cell NHL

Michael L. Wang, Leo I. Gordon, Alexandre V Hirayama, Matthew A Lunning, Ling Shi, Shien Guo, Ana Kostic, Laurie Eliason, Jinender Kumar, Maria Lia Palomba
Journal: Blood
Blood (2023) 142 (Supplement 1): 667.
https://doi.org/10.1182/blood-2023-180014
Published: 2023
Journal Articles

Matching-Adjusted Indirect Comparison (MAIC) of Efficacy and Safety of Lisocabtagene Maraleucel (liso-cel) and Mosunetuzumab for the Treatment (Tx) of Third Line or Later (3L+) Relapsed or Refractory (R/R) Follicular Lymphoma (FL)

Loretta J. Nastoupil, Ashley Bonner, Pearl Wang, Lamees Almuallem, Jigar Desai, Omotayo Fasan, Thalia Farazi, Jinender Kumar, Saurabh Dahiya
Journal: Blood
Blood (2023) 142 (Supplement 1): 2338.
https://doi.org/10.1182/blood-2023-178786
Published: 2023
Journal Articles

A Systematic Literature Review (SLR) and Meta-Analysis of Clinical Evidence of Second Line or Later (2L+) Treatments for Follicular Lymphoma (FL) in Adult Patients

Samantha Craigie, Abril Oliva Ramirez, Emily Rosta, Jigar Desai, Omotayo Fasan, Thalia Farazi, Jinender Kumar
Journal: Blood
Blood (2023) 142 (Supplement 1): 6139.
https://doi.org/10.1182/blood-2023-178738
Published: 2023